All In Biotech

Drug Trial Radar · NCT04919642

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) Tablet in Adult Patients With Advanced Cholangiocarcinoma

Last checked: Nov 19, 2026Latest source record: Jun 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

Dec 7, 2021

Primary completion

Feb 28, 2024

Study completion Feb 28, 2024

Sponsor

Sponsor type
Industry
First posted
Jun 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.

Conditions

  • Cholangiocarcinoma
  • FGFR2 Fusion
  • FGFR2 Gene Mutation
  • FGFR1 Alteration
  • FGFR3 Alteration

Interventions

  • TT-00420Drug

    TT-00420 tablet, administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) in patients with FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor (Cohort A1)Time frame: Through study completion, an average of 9 months.
  2. ORR in patients with FGFR2 fusions who have responded (CR or PR) on at least one previous treatment with an FGFR inhibitor and discontinued due to progressive disease (Cohort A2)Time frame: Through study completion, an average of 9 months.
  3. ORR in patients with FGFR alterations other than FGFR2 fusions (Cohort B)Time frame: Through study completion, an average of 9 months.
  4. ORR in patients without FGFR alterations (wild-type FGFR mutation status) (Cohort C)Time frame: Through study completion, an average of 9 months.

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Cancer Center

    Anchorage, Alaska

  • City of Hope

    Duarte, California

  • University of California, Los Angeles, School of Medicine

    Santa Monica, California

  • USO Oncology Network- Rocky Mountain Cancer Centers

    Denver, Colorado

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • University of Chicago Medical Center - Duchossis Center for Advanced Medicine

    Chicago, Illinois

  • University of Maryland - Marlene and Stewart Greenebaum Cancer Center

    Baltimore, Maryland

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Henry Ford Health Center

    Detroit, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Comprehensive Cancer Center of Nevada

    Las Vegas, Nevada

  • Summit Medical Group - Florham Park Campus

    Florham Park, New Jersey

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Ruttenberg Treatment Center - Mount Sinai

    New York, New York

  • USOR Oncology Network- New York Oncology

    New York, New York

  • Stony Brook University - Long Island Cancer Center

    Stony Brook, New York

  • University of Cincinnati Cancer Institute

    Cincinnati, Ohio

  • University Hospitals Seidman Cancer Center

    Cleveland, Ohio

  • USO Oncology Network-Northwest Cancer Specialists, P.C.

    Portland, Oregon

  • Medical College of South Carolina

    Charleston, South Carolina

  • The University of Tennessee Medical Center

    Knoxville, Tennessee

  • Sarah Cannon Research Institute at Tennessee Oncology

    Nashville, Tennessee

  • Methodist Dallas Medical Center

    Dallas, Texas

  • Parkland Health & Hospital System

    Dallas, Texas

  • University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas

  • Houston Methodist Hospital - Outpatient Center

    Houston, Texas

  • UT MD Anderson Cancer Center

    Houston, Texas

  • USO Oncology Network-Texas Oncology

    Tyler, Texas

  • USO Oncology Network-Virginia Oncology Associates - Brock Cancer Center - Norfolk

    Norfolk, Virginia

  • USO Oncology Network-Oncology and Hematology Associates of Southwest Virginia, Inc.

    Roanoke, Virginia

  • University of Wisconsin School of Medicine and Public Health

    Madison, Wisconsin

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.